Evidence map›Paper›PMID 39008065›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Evaluation of a novel

Yongsheng Liu, Maryam Oroujeni, Yunqi Liao, Anzhelika Vorobyeva, Vitalina Bodenko, Anna Orlova, Mark Konijnenberg, Matilda Carlqvist, Elisabet Wahlberg, Annika Loftenius and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Investigation of aBMC cancer · 2026
    Article
  2. The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yongsheng LiuDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Maryam OroujeniDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Yunqi LiaoDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Anzhelika VorobyevaDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Vitalina BodenkoDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, Uppsala, 751 23, Sweden.
Mark KonijnenbergDepartment of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Matilda CarlqvistAffibody AB, Solna, 171 65, Sweden.
Elisabet WahlbergAffibody AB, Solna, 171 65, Sweden.
Annika LofteniusAffibody AB, Solna, 171 65, Sweden.
Fredrik Y FrejdDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden. vladimir.tolmachev@igp.uu.se.ORCID 0000-0002-6122-1734

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFusion of Affibody molecules with an albumin-binding domain (ABD) provides targeting agents, which are suitable for radionuclide therapy. To facilitate clinical translation, the low immunogenic potential of such constructs with targeting properties conserved is required.

methodsThe HER2-targeting Affibody molecule ZHER2:2891 was fused with a deimmunized ABD variant and DOTA was conjugated to a unique C-terminal cysteine. The novel construct, PEP49989, was labelled with

resultsThe maximum molar activity of 52 GBq/µmol [

conclusionIn preclinical studies, [

Indexed as

Erb-b2 Receptor Tyrosine KinasesLutetiumRadioisotopesAlbuminsAnimalsCell Line, TumorFemaleHumansIsotope LabelingMiceProtein DomainsRadiopharmaceuticalsRecombinant Fusion ProteinsTissue DistributionAlbuminsErb-b2 Receptor Tyrosine KinasesLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsRecombinant Fusion ProteinsAffibody moleculesAlbumin binding domainLutetium-177Therapy

Identifiers

PMID39008065
PMCPMC11527907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.